Data from the Nexvax2 study shows celiac patients exposed to gluten react within two hours and experience nausea and vomiting, not the classic lower digestive symptoms commonly associated with celiac disease.
Continue ReadingThe Celiac Disease Foundation, the nation’s leading disease advocacy organization for celiac disease, announces the appointment of officers to its Board of Directors.
Continue ReadingOn December 11, 2019, CEO Marilyn G. Geller was with Senator Blumenthal's legislative staff as Senator Richard Blumenthal (D-CT) introduced S.3021: Gluten in Medicine Disclosure Act of 2019 to the Senate. The Celiac Disease Foundation is proud to be a partner in this effort.
Continue ReadingA group of celiac patients and caregivers from all 50 states will convene in Washington, DC to hear from researchers, federal government representatives, and celiac advocates for a National Patient Advocacy Summit to learn how to become Celiac Disease Foundation State Advocacy Ambassadors.
Continue ReadingAfter decades of pleading with our federal government to take celiac disease as seriously as it does other diseases with comparable patient impact, yesterday, the U.S. House and Senate each passed, and President Trump has signed, the FY2020 Federal budget resolution.
Continue ReadingImmunogenX, a clinical stage biotherapeutics company, has published the results of their phase 2 trial testing latiglutenase—an orally administered treatment for celiac disease (CD). Latiglutenase was shown to be safe…
Continue ReadingThere is currently no easy way to diagnose celiac disease in patients already following a gluten-free diet. In order for celiac disease blood tests to be accurate, patients on a…
Continue ReadingResearchers at the Beth Israel Deaconess Medical Center, including Celiac Disease Foundation Medical Advisory Board Member Dan Leffler, conducted a study to determine the effects of the gluten-free diet (GFD)…
Continue ReadingScientist at Cincinnati Children’s Hospital awarded $1.5 million grant to study stem cells from patients with genetic diseases, including celiac disease, that impair one’s ability to properly absorb nutrients to help develop new therapies for malnutrition.
Continue ReadingWe put together a list of some of the most common perceived barriers to participating in clinical trials, and how to overcome them.
Continue ReadingLast month, the Celiac Disease Foundation had the privilege of sponsoring the 2024 International Celiac Disease Symposium in Sheffield, UK. As the first patient advocate invited to chair and present on a scientific panel, CEO Marilyn Geller co-chaired the End Points in Clinical Trials session with Dr. Francisco Leon, CEO...